9101 Toxicity report of a phase I/II dose escalation study in inoperable locally advanced non-small cell lung cancer with helical tomotherapy and concurrent chemotherapy

Bral, Samuel; Versmessen, Harijati; Duchateau, Michaël; Schallier, Denis; Everaert, Hendrik; Storme, Guy

doi:10.1016/s1359-6349(09)71814-2

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study revealed that there was no difference in the 2‐year survival rate between HT and step and shoot (SMLC)‐IMRT, but oral toxicity caused by HT was lower than that caused by SMLC‐IMRT (Table ). iv Lung cancer: the results of 12 observational studies and 1 CCT ( n = 442) reported that the 1‐, 2‐, and 3‐year SRs, the 1‐year disease‐free SR, and the 2‐year progression‐free SRs after HT for breast cancer were 60.5%; 55–56%; 55–56%; 62.5%; 66%; and 50%, respectively (Table ). The main toxicities were acute esophageal toxicity and lung toxicity; most were mild (G2) with few G3 toxicities.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Helical tomotherapy for cancer treatment: a rapid health technology assessment

Yang

Shen

et al. 2014

J Evidence Based Medicine

View full text Add to dashboard Cite

The evidence of this study showed that, HT is safe and effective in clinic. But the abovementioned conclusion needs to be verified by conducting more high-quality studies with long-term follow-up. The costs of HT in procurement, maintenance, and application are high; and the skills, training, and qualification of operators are required. We suggest that the procurement of HT should be reduced; it should be allocated rationally and effectively used after comprehensive assessment in China's cancer epidemiology characteristics, health resource allocation, disease burden, medical service level, etc.; and also high-quality studies with long-term follow-up should be financially supported on the basis of establishing projects, so as to provide local evidence and consistently guide and improve scientific decision-making.

show abstract

Section: Resultsmentioning

confidence: 99%

“…A total of 145 original studies ( n = 6992) were included in the analysis (mainly including CCTs and observational studies) (Table ). Fourteen types of cancer (82%) were assessed in the present study.…”

Section: Resultsmentioning

confidence: 99%

Helical tomotherapy for cancer treatment: a rapid health technology assessment

Yang

Shen

et al. 2014

J Evidence Based Medicine

View full text Add to dashboard Cite

show abstract

“…Another phase I/II study was conducted in Brussels University Hospital (34) to determine the MTD, but this escalated not only the total dose but also the fraction size concurrently with CT. Fraction dose was increased by 6% starting at 2 Gy, with 2.48 Gy being the maximum.…”

Section: Hypofractionationmentioning

confidence: 99%

Definitive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer: Dose and Fractionation

Dağoğlu¹,

Sule²,

Arifoglu³

et al. 2015

Balkan Med J

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related mortality for both men and women. Among all cases, non-small cell lung cancer (NSCLC) accounts for 70-80% and almost half of the cases are considered to be locally advanced (LA) or unresectable disease at first presentation (1). Until only a decade ago, conventional fractionated radiotherapy (RT) alone applied at a dose of 60 Gy in 2 Gy fractions over 6 weeks was accepted as the standard nonsurgical treatment for these patients. However, the results were discouraging as the median survival obtained was less than a year and the 2-year survival rate did not go above 15-20% (2).After the impact of RT dose for lung cancer was established (3), a number of trials were structured in the quest for better local control and overall survival by either dose escalation or shortening the total treatment time through conventional/altered fractionation, even in combination with chemotherapy (CT) and other targeted agents.This review summarises the results of significant trials on dose and altered fractionation in the treatment of LA-NSCLC with an emphasis on possible future perspectives. The included trials were evaluated under two main titles as "Dose and Dose Escalation" and "Treatment Duration and Altered Fractionation". It should be noted that there is not always a distinct differentiation among the trials as some of the studies address both aspects. In the case of overlap, trials were grouped according to the main hypothesis which they were designed to answer. DOSE AND DOSE ESCALATIONSeveral studies have confirmed the relationship for dose and tumour response that led to an ameliorated local control and survival (Table 1).The first trial that validated the advantage of dose escalation for LA-NSCLC was the Radiation Therapy Oncology Group (RTOG) 73-01 trial, where 376 patients were randomised into four arms (2). Three arms included standard fractionation with doses of 40, 50 and 60 Gy in 2 Gy fractions and the fourth arm included a split course RT that was applied in 4 Gy fraction size to a total dose of 40 Gy over 5 weeks with a 3 week interruption in the middle. The overall 3 year intrathoracic failure rate was 33% for patients treated in the 60 Gy arm; this was significantly lower when compared to the other arms, with reDefinitive radiotherapy plays a major role in the treatment of locally advanced non-small cell lung cancer (LA NSCLC). After the impact of RT dose for lung cancer was established, a number of trials were structured with the aim of better local control and overall survival by either dose escalation or shortening the total treatment time through conventional/altered fractionation, even in combination with chemotherapy (CT) and other targeted agents. In spite of the increased number of these studies, the optimal dose or fractionation still remains to be determined. Another aspect questioned is the incorporation of these higher doses and shorter treatment times with chemotherapy or targeted agents. This review summarises the results of significant trials on d...

show abstract

9101 Toxicity report of a phase I/II dose escalation study in inoperable locally advanced non-small cell lung cancer with helical tomotherapy and concurrent chemotherapy

Cited by 2 publications

References 0 publications

Helical tomotherapy for cancer treatment: a rapid health technology assessment

Helical tomotherapy for cancer treatment: a rapid health technology assessment

Definitive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer: Dose and Fractionation

Contact Info

Product

Resources

About